For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Minimal Homozygous Endothelial Deletion of Eng with VEGF Stimulation Is Sufficient to Cause Cerebrovascular Dysplasia in the Adult MouseChoi E.-J.a · Walker E.J.a · Shen F.a · Oh S.P.d · Arthur H.M.e · Young W.L.a–c · Su H.a
aDepartment of Anesthesia and Perioperative Care, Center for Cerebrovascular Research, and Departments of bNeurological Surgery and cNeurology, University of California, San Francisco, San Francisco, Calif., and dDepartment of Physiology and Functional Genomics, Shands Cancer Center, University of Florida, Gainesville, Fla., USA; eInstitute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle, UK Corresponding Author
Hua Su, MD
Department of Anesthesia and Perioperative Care
University of California, San Francisco, 1001 Potrero Avenue, Room 3C-38
San Francisco, CA 94110 (USA)
Tel. +1 415 206 3162, E-Mail email@example.com
Background: Brain arteriovenous malformations (bAVMs) represent a high risk for hemorrhagic stroke, leading to significant neurological morbidity and mortality in young adults. The etiopathogenesis of bAVM remains unclear. Research progress has been hampered by the lack of animal models. Hereditary Hemorrhagic Telangiectasia (HHT) patients with haploinsufficiency of endoglin (ENG, HHT1) or activin receptor-like kinase 1 (ALK1, HHT2) have a higher incidence of bAVM than the general population. We previously induced cerebrovascular dysplasia in the adult mouse that resembles human bAVM through Alk1 deletion plus vascular endothelial growth factor (VEGF) stimulation. We hypothesized that Eng deletion plus VEGF stimulation would induce a similar degree of cerebrovascular dysplasia as the Alk1-deleted brain. Methods: Ad-Cre (an adenoviral vector expressing Cre recombinase) and AAV-VEGF (an adeno-associated viral vector expressing VEGF) were co-injected into the basal ganglia of 8- to 10-week-old Eng2f/2f (exons 5 and 6 flanked by loxP sequences), Alk12f/2f (exons 4–6 flanked by loxP sequences) and wild-type (WT) mice. Vascular density, dysplasia index, and gene deletion efficiency were analyzed 8 weeks later. Results: AAV-VEGF induced a similar degree of angiogenesis in the brain with or without Alk1- or Eng-deletion. Abnormally patterned and dilated dysplastic vessels were found in the viral vector-injected region of Alk12f/2f and Eng2f/2f brain sections, but not in WT. Alk12f/2f mice had about 1.8-fold higher dysplasia index than Eng2f/2f mice (4.6 ± 1.9 vs. 2.5 ± 1.1, p < 0.05). However, after normalization of the dysplasia index with the gene deletion efficiency (Alk12f/2f: 16% and Eng2f/2f: 1%), we found that about 8-fold higher dysplasia was induced per copy of Eng deletion (2.5) than that of Alk1 deletion (0.3). ENG-negative endothelial cells were detected in the Ad-Cre-treated brain of Eng2f/2f mice, suggesting homozygous deletion of Eng in the cells. VEGF induced more severe vascular dysplasia in the Ad-Cre-treated brain of Eng2f/2f mice than that of Eng+/– mice. Conclusions: (1) Deletion of Eng induces more severe cerebrovascular dysplasia per copy than that of Alk1 upon VEGF stimulation. (2) Homozygous deletion of Eng with angiogenic stimulation may be a promising strategy for development of a bAVM mouse model. (3) The endothelial cells that have homozygous causal gene deletion in AVM could be crucial for lesion development.
© 2012 S. Karger AG, Basel
Brain arteriovenous malformations (bAVMs) cause spontaneous intracranial hemorrhage (ICH) leading to a high risk of stroke especially in children and young adults . The pathogenesis and environmental risk factors for bAVMs remain elusive. The only available treatments for bAVM are removing the mass of abnormal vessels or occluding them by injecting embolic materials or by radiation. There is no specific medical therapy available to prevent the development or decrease the rate of bAVM rupture. Advances in bAVM research have been hindered by a lack of animal models for investigating disease mechanisms and testing new therapies. Although over 95% of bAVMs are sporadic, the familial cases are primarily seen in patients with Hereditary Hemorrhagic Telangiectasia (HHT). HHT patients have a greatly increased prevalence of bAVM than the general population . An autosomal dominant disorder, HHT is most commonly caused by functional haploinsufficiency in one of two genes: endoglin (ENG; HHT1) or activin receptor-like kinase 1 (ALK1; HHT2). Among subtypes, HHT1 patients tend to develop more bAVMs (∼20%) than HHT2 patients (∼2%) .
Endoglin and ALK1 are type III and type I transmembrane receptors, respectively, for the transforming growth factor-β (TGF-β) superfamily . Both of them are primarily expressed in endothelial cells (ECs) and highly induced in activated endothelium during angiogenesis. In general, ALK1 signaling regulates EC proliferation and migration, and its function is promoted by ENG . Previously, we demonstrated that haploinsufficiency of either Eng (Eng+/–) or Alk1 (Alk1+/–) and an angiogenic insult are required for the development of cerebrovascular abnormalities in adult mice . In addition, there were more dysplastic vessels formed in the brain of Eng+/– than Alk1+/– mice in response to vascular endothelial growth factor (VEGF) stimulation , which replicated the relative penetrance of bAVM observed in HHT patients. However, abnormal vessel formation in the brain of Eng+/– and Alk1+/– mice was at the capillary level, which recapitulated perinidal dysmorphic and dilated capillaries [6,7], but not abnormally tangled large vessels seen in human bAVM nidus.
To accomplish homozygous Alk1-deletion in the adult mouse brain, we utilized the Cre/loxP system. This system includes a genetically modified mouse that has the targeted gene or a part of the target gene flanked by two loxP sequences. Cre recombinase can be introduced by transgenic techniques (establishment of a Cre driver transgenic mouse line or direct administration of Cre-expressing vectors) or Cre protein administration. Cre mediates recombination of the two loxP sites, which results in the deletion of the sequence flanked by the loxP (online suppl. fig. 1; for all online suppl. material, see www.karger.com?doi=10.1159/000337762). In Alk12f/2f mice, exons 4–6 on both alleles are flanked by loxP sequences. By injecting Ad-Cre (an adenoviral vector expressing Cre) and AAV-VEGF into the basal ganglia, we deleted exons 4–6 of the Alk1 gene in that region (online suppl. fig. 2) and induced focal angiogenesis, resulting in a cerebrovascular phenotype that recapitulated many key aspects of human bAVM , including irregularly dilated vessel morphology, arteriovenous shunting, and inflammatory cell infiltration. Based on the observation that HHT1 patients have a higher incidence of bAVM than HHT2 patients  and our data that Eng+/– mice develop more dysplastic vessels in their brain than Alk1+/– mice upon VEGF stimulation , in this study, we tested the hypothesis that co-injection of Ad-Cre and AAV-VEGF into the brain of Eng2f/2f mice induces more severe cerebrovascular dysplasia than Alk12f/2f mice.
Experimental procedures for using laboratory animals were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, San Francisco (UCSF). Adult (8- to 10-week-old) Alk12f/2f mice (exons 4–6 flanked by loxP sites)  and Eng2f/2f (exons 5 and 6 flanked by loxP sites)  mice were used. Adult C57BL/6 wild-type (WT; Jackson Laboratory, Bar Harbor, Me., USA) mice were used as control. ROSA26 reporter (R26R; Jackson Laboratory) mice were used to test the deletion efficiency of the floxed allele (2f) by Ad-Cre stereotactic injection (online suppl. fig. 3).
Adenoviral vectors with cytomegalovirus (CMV) promoter driving Cre recombinase (Ad-Cre) or green fluorescent protein (Ad-GFP) expression were purchased from Vector Biolabs (Philadelphia, Pa., USA). Adeno-associated viral vectors with CMV promoter driving VEGF (AAV-VEGF) or β-galactosidase (AAV-lacZ) expression were prepared as described previously [11,12]. Adenoviral (2 × 107 plaque forming unit) and AAV (2 × 109 genome copies) vectors were co-injected stereotactically into the basal ganglia of mice in different combinations as described previously .
Procedures for vascular casting with microfil (Flow Tech Inc., Carver, Mass., USA) and in vivo vascular labeling with lectin (Vector Laboratories, Burlingame, Calif., USA) were described previously [8,13]. Two coronal sections of the lectin-perfused brain per mouse, 0.5 mm rostral and 0.5 mm caudal to the injection site, were chosen and stained with an antibody against α-smooth muscle actin (α-SMA; 1:1,000; Sigma-Aldrich, St. Louis, Mo., USA). Three areas (right and left of, and underneath the injection site) of each section were captured under ×20 microscopic objective lens. Capillaries (lectin positive and α-SMA negative) in each picture were counted separately using NIH Image 1.63 software by three blinded investigators [5,8]. Vascular density was calculated as the mean of capillaries obtained from 6 images per animal. A vessel was considered dysplastic when it had a diameter >15 µm and was α-SMA negative . In general, the diameter of a normal capillary is 3–8 µm . Dysplasia index was defined as the number of capillaries >15 µm per 200 capillaries.
Sections of the lectin-perfused brain were stained with primary antibodies against β-galactosidase (1:1,000, Abcam Inc., Cambridge, Mass., USA) or ENG (1:50; BD Pharmingen, Franklin Lakes, N.J., USA). Expression of β-galactosidase was subsequently detected by a fluorescent secondary antibody (Alexa Fluor 594 anti-rat IgG; Invitrogen, Carlsbad, Calif., USA). ENG-positive staining was visualized using a biotin-conjugated secondary antibody (anti-rat IgG; 1:500; Vector Laboratories) and the standard ABC method (Vector immunodetection kit; Vector Laboratories).
Genomic DNA was isolated from brain tissue around the virus injection sites and tails using the QIAamp DNA Micro Kit (Qiagen). Quantitative real-time PCR (qPCR) was performed using the QuantiTect SYBR Green PCR Kit (Qiagen) and PCR cycler (Mx3000P QPCR System, Agilent Technologies), following the manufacturer’s protocol. The primers used for genomic DNA qPCR are summarized in table 1.
Data are presented as mean ± SD. One-way analysis of variance (ANOVA) was used to determine a statistical significance among groups, followed by pairwise multiple comparisons using the post-hoc Tukey test. A p value <0.05 was considered statistically significant.
Malformed vessels were observed in both Alk12f/2f and Eng2f/2f adult mouse brain at the Ad-Cre/AAV-VEGF injection site, while normal angiogenesis was observed in the WT brain (fig. 1). Histological analysis of lectin-perfused brain sections showed that WT mice treated with AAV-VEGF had higher mean vascular density than mice treated with AAV-lacZ (202 ± 43 vs. 111 ± 15, p < 0.05; fig. 2a). VEGF induced a similar degree of angiogenesis in the experimental mice (WT: 180 ± 43, Alk12f/2f: 219 ± 49, and Eng2f/2f: 195 ± 59, p = 0.2; fig. 2b). The dysplasia index was significantly higher in the brain of Alk12f/2f and Eng2f/2f mice injected with Ad-Cre/AAV-VEGF as compared to similarly treated WT mice (Alk12f/2f: 4.6 ± 1.9 and Eng2f/2f: 2.5 ± 1.1 vs. WT: 0.5 ± 0.4, p < 0.05; fig. 2c). Injection of Ad-GFP (a control viral vector for Ad-Cre) with AAV-VEGF to Alk12f/2f or Eng2f/2f mice led to normal angiogenesis (data not shown). Injection of AAV-lacZ (a control viral vector for AAV-VEGF) with Ad-Cre had no effect on the vascular density and structure (data not shown).
Interestingly, injection of Ad-Cre and AAV-VEGF induced more cerebrovascular dysplasia in Alk12f/2f than Eng2f/2f mice (4.6 ± 1.9 vs. 2.5 ± 1.1, p <0.05; fig. 2c), which contradicted our hypothesis. To investigate why Alk12f/2f mice had a more severe dysplastic phenotype than Eng2f/2f mice, we analyzed the gene deletion efficiency mediated by Ad-Cre. The effectiveness of Ad-Cre-mediated floxed allele (2f) deletion has been tested in ROSA26 reporter (R26R) mice . In R26R mice, a transgene containing the loxP-flanked STOP cassette (stopper) introduced between the promoter and lacZ reporter gene is inserted into the ROSA 26 locus. In the presence of Cre, the stopper is deleted by recombination, followed by activation of lacZ expression (online suppl. fig. 3). Further analysis showed that Ad-Cre-mediated homozygous gene deletion (lacZ gene expression) demonstrated a mosaic pattern in some of the ECs (fig. 3a). ENG-negative ECs were detected in the angiogenic foci of the Ad-Cre/AAV-VEGF-injected Eng2f/2f brain (fig. 3b), suggesting that Ad-Cre-mediated homozygous Eng deletion in some of the ECs.
To quantify the gene deletion efficiency, we performed qPCR. We first examined the level of Alk1- and Eng-floxed alleles that contain two loxP sites (2f) in genomic tail DNA. Matrix metalloproteinase-9 (Mmp-9) gene was used as an internal quantitative control. When we compared Alk1- and Eng-floxed alleles to Mmp-9, the ratio was 1:1 in both instances, confirming that the qPCR condition we used could amplify both floxed alleles and an internal positive control gene in an unbiased way (fig. 4a). Next, the copies of Alk1- or Eng-floxed alleles in the Ad-Cre-treated brain sections were analyzed. Genomic DNA was isolated from brain tissue containing the angiogenic foci where the cells were infected with both Ad-Cre and AAV-VEGF. Ad-Cre and AAV-VEGF-injected Alk12f/2f and Eng2f/2f mice had similar vessel densities in the viral vector injection sites, suggesting that Ad- and AAV-mediated gene transduction and expression were equivalent in these two groups of mice. The copy numbers of Alk1- and Eng-floxed 2f alleles were normalized to the copy number of Mmp-9. The gene deletion was determined by comparing the copies of the floxed allele in the brain to that in the tail. About 16% of the Alk1-floxed allele was deleted in the Ad-Cre-injected brain of Alk12f/2f mice, while only 1% of the Eng-floxed allele was deleted in the brain of similarly treated Eng2f/2f mice (fig. 4b). Thus, more severe dysplasia seen in Alk12f/2f mice compared to Eng2f/2f mice appears to be due to more effective gene deletion.
To analyze whether similar dysplasia would have developed in the brain of Eng2f/2f and Alk12f/2f mice, if the gene deletion efficiency was the same, we divided the mean dysplasia index of these mice by the mean deletion efficiency of each gene. We found that deletion of Eng resulted in more dysplastic vessels per gene copy than that of Alk1 in the adult mouse brain (Eng2f/2f: 2.5 vs. Alk12f/2f: 0.3; fig. 4c). To test if homozygous deletion of Eng is a more potent dysplasia inducer than heterozygous deletion, the value of dysplasia index per deleted gene copy in Eng2f/2f mice was further compared with that observed in our previously published study using Eng+/– mice that had 50% gene deletion . Eng2f/2f mice treated with Ad-Cre/AAV-VEGF had a higher dysplasia index/deletion of gene copy than Eng+/– mice treated with AAV-VEGF  (Eng2f/2f: 2.5 vs. Eng+/–: 0.06; fig. 4c). Eng2f/2f mice also had more severe vascular dysplasia (larger dysplastic vessels at a macroscopic level; fig. 1) than Eng+/– mice in which the dysplasia was at the capillary level  (fig. 4c), suggesting that homozygous deletion of Eng is necessary in the induction of severe cerebrovascular dysplasia.
In this study, we compared the effectiveness of Ad-Cre and AAV-VEGF in the induction of cerebrovascular malformation in adult Alk12f/2f and Eng2f/2f mice. We found that (1) Ad-Cre-mediated gene deletion was less effective in the brain of Eng2f/2f mice compared to Alk12f/2f mice, and (2) more dysplastic vessels were induced per copy of Eng deletion than that of Alk1 deletion after VEGF stimulation. In addition, VEGF caused more severe dysplasia (macroscopic level) in the Ad-Cre-injected Eng2f/2f brain than in the Eng+/– brain (capillary level), suggesting that homozygous deletion of Eng is more potent in the induction of vascular dysplasia and may be necessary for the development of a fully-formed AVM. Therefore, these observations are consistent with the notion that loss of heterozygosity of Eng (Eng-null) due to somatic mutations in the normal allele in a subset of ECs – perhaps quite small – could be the trigger for AVM development in HHT.
The R26R transgenic mice have been used to assess the efficiency of Cre-mediated conditional gene deletion in various organs and cell types [16,17,18,19]. We previously demonstrated that more than 50% of ECs, neurons, and astrocytes in the Ad-Cre-injected basal ganglia of R26R mice showed lacZ expression by immunohistochemical analysis, indicating that Ad-Cre-mediated gene deletion efficiency in the brain of R26R mice was >50% . Here, using qPCR analysis, we found that there was much less gene deletion in the brain of Alk12f/2f and Eng2f/2f mice with the same Ad-Cre viral vector, virus dose, and injection method. We showed a similar degree of angiogenesis in the brain of Alk12f/2f and Eng2f/2f mice induced by co-injection of Ad-Cre and AAV-VEGF, indicating the same degree of viral transduction. Further, Cre-mediated gene deletion was evidenced by reporter gene expression and reduced expression of the target gene in the angiogenic foci (fig. 3). However, we observed different gene deletion efficiency in these mice (Alk1: 16% vs. Eng: 1%). Thus, the efficiency of Cre-mediated gene deletion varies in targeted genes, suggesting that R26R mice may not be a reliable model to assess effectiveness of Cre in deletion of certain target genes.
Although more severe dysplasia was observed in the Ad-Cre/AAV-VEGF-injected brain of Alk12f/2f mice than Eng2f/2f mice, there were more dysplastic vessels formed per copy of Eng deletion than that of Alk1. This finding suggests that more severe dysplasia might develop in Eng2f/2f mice if equivalent copies of Eng were deleted as compared to Alk12f/2f mice. To improve deletion of the Eng gene, higher doses of Ad-Cre or other conditional Cre delivery approaches, such as an AAV-Cre vector and the ROSA-CreER (ER: estrogen receptor) system in which Cre expression is induced by tamoxifen treatment, may be utilized. AAV viral vector has been known to express exogenous protein longer than Ad viral vector following transduction . In the ROSA-CreER system, Cre becomes ubiquitously and robustly active upon treatment of a chemical compound tamoxifen , and the Cre expression can also be enhanced by multiple treatments of tamoxifen. In addition, employing Eng2f/– mice through cross-breeding between Eng2f/2f and Eng+/– mice might be an option to achieve efficient homozygous deletion of Eng.
Evidence obtained from analysis of human AVM indicates that haploinsufficiency of ENG may not be sufficient to trigger lesion development. A case report of a HHT1 patient showed a 50% reduction in the endoglin/PECAM-1 ratio in the presumed normal blood vessels adjacent to lung and brain AVM . In sporadic human bAVM tissue, there was no gross defect in endoglin expression in the endothelium . We found that in mice, despite minimal (∼1%) deletion of Eng in the brain of Ad-Cre-treated Eng2f/2f mice, more severe cerebrovascular dysplasia formed after VEGF stimulation compared to Eng+/– mice, i.e., 50% Eng deletion . Eng-null ECs were found in the brain of Ad-Cre-treated Eng2f/2f mice, suggesting homozygous deletion of Eng in these cells causing mosaicism (fig. 3). This mosaic expression of ENG might be due to the accessibility of Eng to Cre that can be affected by transduction efficiency of Ad-Cre and effectiveness of Cre in mediating recombination of the loxP sites in the floxed allele. We have demonstrated in our previous study  that injection of Ad-Cre (2 × 107 PFU) into the basal ganglia of R26R mice resulted in targeted gene deletion in 51% of ECs. Further, the efficiency of Cre-mediated gene deletion varies among genes and is dependent on the genomic position of the loxP-containing targeted allele . We found that Cre is relatively ineffective in mediating recombination of the loxP sites in the Eng-floxed allele. Therefore, the homozygous deletion of Eng might occur in a small percentage of ECs. Thus, more dysplasia in the brain of Ad-Cre-treated Eng2f/2f mice suggests that homozygous mutation of Eng in a small number of ECs is sufficient to cause cerebrovascular malformations upon angiogenic stimulation. In addition, homozygous mutations appear to be an operant mechanism in the development of cavernous malformation, a related cerebrovascular disease causing hemorrhagic stroke [25,26]. Additional study is thus needed to address mosaic gene expression patterns in human bAVM.
In summary, the comparison of heterozygous and homozygous Eng deletion in our mouse model of vascular malformation demonstrates that there is a distinct difference in lesional phenotype induction between heterozygous and homozygous gene deletion. While the Eng+/– mice presented with only minimal irregular capillaries, the Ad-Cre-treated Eng2f/2f mice with homozygous Eng deletion in a few ECs developed macroscopic level of dysplasia after VEGF stimulation. Our data are consistent with the hypothesis that the disease is contingent on loss of both gene copies; further study is needed to examine whether loss of heterozygosity (homozygous gene deletion) in ECs exists in human bAVM.
The authors thank Tony Pourmohamad for assistance with statistical analysis, Douglas A. Marchuk (Duke University Medical Center) for critical discussion and review of the manuscript, Voltaire Gungab for assistance with manuscript preparation, and the other members of the UCSF BAVM Study Project (http://avm.ucsf.edu) for their support. This study was supported in part by grants from the National Institutes of Health, T32 GM008440 (E.W.), R01 NS027713 (W.L.Y.), R21 NS070153 (H.S.), and P01-NS044155 (W.L.Y. and H.S.); from the American Heart Association, AHA SDG 0535018N (H.S.); and from the British Heart Foundation (H.M.A.).
Hua Su, MD
Department of Anesthesia and Perioperative Care
University of California, San Francisco, 1001 Potrero Avenue, Room 3C-38
San Francisco, CA 94110 (USA)
Tel. +1 415 206 3162, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.